Ascorbic Acid Tablets IP 300 mg Manufacturer in India – Healthy Life Pharma Pvt. Ltd.

Ascorbic Acid Tablets IP 300 mg | Manufacturer
Product image for Ascorbic Acid Tablets IP 300 mg Manufacturer; contract manufacturing, oem & quality control.
Product Information
| Generic Name | Ascorbic Acid |
|---|---|
| Manufacturer | Healthy Life Pharma Pvt. Ltd. |
| HSN Code | 30045035 |
| Pharmacopoeia | IP |
| Product Type | Tablet |
| Category | Vitamin and Mineral Supplements |
| Subcategory | Vitamin and Mineral Supplements |
| Active Ingredient | Ascorbic Acid |
| Strength | 300 mg |
| Dosage Form | Tablet |
| Pack Size | 10 x 10 Tablets / Box (Alu-Alu / Blister) |
| Route of Administration | Oral |
| Prescription Required | Yes |
| Therapeutic Category | Vitamin and Mineral Supplements |
Medicine Details & Safety
| Short Description | Healthy Life Pharma invites contract and third-party manufacturing enquiries for Ascorbic Acid Tablets IP 300 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements. | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Approved Uses / Indications | 1. Prevention and treatment of clinical vitamin and mineral deficiency states. 2. Nutritional supplementation during convalescence, increased physiological demand, pregnancy, and geriatric care. | ||||||||||||||||||||||||
| Full Description | Healthy Life Pharma invites contract and third-party manufacturing enquiries for Ascorbic Acid Tablets IP 300 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements. Product technical specifications
Product technical specifications
Manufacturing capabilities and infrastructureFor Ascorbic Acid Tablets IP 300 mg, assess the approved formulation process, equipment suitability, batch scale and in-process controls for the Tablet presentation. Confirm environmental requirements and validated process before production.Quality control and assuranceRequest the approved finished-product specification for Ascorbic Acid Tablets IP 300 mg, including applicable identity, assay, uniformity and performance tests for the Tablet presentation. Confirm analytical methods, acceptance criteria and batch release documentation, including COA availability.Primary and secondary packagingThe catalogue pack for Ascorbic Acid Tablets IP 300 mg is 10 x 10 Tablets / Box (Alu-Alu / Blister). Confirm primary packaging compatibility, stability evidence, artwork, batch coding and leaflet requirements against the approved specification.Contract manufacturing and private labelSubmit the target market, strength, pharmacopoeial specification, forecast volume and brand artwork. Agree feasibility, batch size, quality agreement, production schedule and release criteria before execution. | ||||||||||||||||||||||||
| Dosage Instructions | Administer orally once daily with meals, or as recommended by the healthcare provider. Swallow whole with water; do not exceed the recommended dietary intake. | ||||||||||||||||||||||||
| Side Effects | Common: Mild gastrointestinal fullness, transient dark stools (with iron), mild nausea. Uncommon: Diarrhea, mild skin flushing, headache. Rare: Allergic hypersensitivity reactions, hypervitaminosis from excessive chronic intake. | ||||||||||||||||||||||||
| Warnings and Precautions | Recommended Allowances: Do not consume in doses exceeding upper tolerable limits without clinical oversight. Renal Compromise: Exercise caution with fat-soluble vitamins or mineral supplements in severe renal impairment. Keep safely out of reach of children. | ||||||||||||||||||||||||
| Contraindications | 1. Known hypersensitivity to any vitamin or active mineral ingredient in the tablet. 2. Preexisting hypervitaminosis or hypercalcemia. 3. Severe renal stone disease (for high-dose calcium/ascorbic acid combinations). | ||||||||||||||||||||||||
| Drug Interactions | 1. Tetracyclines & Fluoroquinolones: Chelation with divalent/trivalent minerals reduces antibiotic absorption; separate by 2 hours. 2. Antiepileptics (Phenytoin): Folate co-administration may alter serum anticonvulsant levels. 3. Levodopa: High doses of pyridoxine may diminish levodopa therapeutic antiparkinsonian response. |
Frequently Asked Questions
| Question | Answer |
|---|---|
| Can I request third-party manufacturing for Ascorbic Acid Tablets IP 300 mg? | Submit your brand, quantity and packaging requirements for manufacturing feasibility review. |
| Which pharmacopoeial standard applies for Ascorbic Acid Tablets IP 300 mg? | The source specification is IP; confirm the required standard before contracting. |
| What quality tests are applicable for Ascorbic Acid Tablets IP 300 mg? | Request the approved finished-product specification and batch testing plan. |
| Can packaging be customized for Ascorbic Acid Tablets IP 300 mg? | Submit artwork and pack requirements for technical and regulatory review. |
| How do I request a manufacturing quotation for Ascorbic Acid Tablets IP 300 mg? | Provide forecast volume, target market, strength and packaging requirements. |
Related Products
✚
Ascorbic Acid Tablets BP 500 mg ExporterView product →
✚
Ascorbic Acid Tablets BP 500 mg ManufacturerView product →
✚
Ascorbic Acid Tablets BP 500 mg SupplierView product →
✚
Ascorbic Acid Tablets IP 100 mg ExporterView product →
✚
Ascorbic Acid Tablets IP 100 mg ManufacturerView product →
✚
Ascorbic Acid Tablets IP 100 mg SupplierView product →
✚
Ascorbic Acid Tablets IP 300 mg ExporterView product →
✚
Ascorbic Acid Tablets IP 300 mg SupplierView product →
✚
Calcium Gluconate Tablets IP 500 mg ExporterView product →
✚
Calcium Gluconate Tablets IP 500 mg ManufacturerView product →
✚
Calcium Gluconate Tablets IP 500 mg SupplierView product →
✚
Cholecalciferol Granules Tablets ExporterView product →
